Carbapenems, Monobactams, and Carbapenem-Resistant Organisms

Correct Answer

B — Carbapenems

Rationale

Within the beta-lactam antibiotic family, each subclass is defined by the scaffold fused to the core four-membered beta-lactam ring. Carbapenems belong to the carbapenem scaffold subtype, distinguished by a five-membered ring with a carbon (rather than sulfur) at position 1 and a double bond, conferring their exceptional stability against most clinically significant beta-lactamases. Penams are the scaffold of penicillins. Cephems are the scaffold of cephalosporins. Monobactams have a single ring with no fused second ring.

Correct Answer

D — Aztreonam

Rationale

Aztreonam is the only monobactam in clinical use. Monobactams contain a single four-membered beta-lactam ring with no fused second ring — a monocyclic structure distinct from all other beta-lactam subclasses. Meropenem and imipenem are carbapenems. Ceftazidime is a third-generation cephalosporin (cephem scaffold).

Correct Answer

A — Dehydropeptidase-I inhibitor

Rationale

Cilastatin is classified as a dehydropeptidase-I inhibitor — an enzyme inhibitor, not an antibiotic. It is co-formulated with imipenem to prevent rapid degradation of imipenem by the renal tubular enzyme dehydropeptidase-I. Cilastatin is not a beta-lactamase inhibitor (which would target bacterial enzymes) and has no antibacterial activity of its own. Imipenem is the carbapenem antibiotic in the pair; cilastatin is its pharmacokinetic partner.

Correct Answer

C — Siderophore cephalosporin

Rationale

Cefiderocol is classified as a siderophore cephalosporin — a novel cephalosporin conjugated to a catechol siderophore that allows the drug to exploit bacterial iron-transport systems to bypass outer membrane permeability barriers. This class label distinguishes it from standard cephalosporins and from carbapenems, monobactams, and glycopeptides, which are entirely different antibiotic classes. Knowing the class name is the task here.

Correct Answer

B — Meropenem-vaborbactam

Rationale

Meropenem-vaborbactam pairs the carbapenem meropenem with vaborbactam, a cyclic boronate beta-lactamase inhibitor — a structural class distinct from both classical inhibitors and from diazabicyclooctane inhibitors such as avibactam and relebactam. Imipenem-cilastatin-relebactam pairs a carbapenem with relebactam, a diazabicyclooctane inhibitor (not a boronate). Ceftazidime-avibactam pairs a cephalosporin with avibactam. Aztreonam-avibactam pairs a monobactam with avibactam. The combination class label for the correct answer is carbapenem plus cyclic boronate inhibitor.

Correct Answer

A — Relebactam

Rationale

Relebactam is the novel beta-lactamase inhibitor in the three-drug combination imipenem-cilastatin-relebactam. It is a diazabicyclooctane inhibitor active against Class A carbapenemases including Klebsiella pneumoniae carbapenemase and Class C AmpC enzymes. Cilastatin is the dehydropeptidase-I inhibitor already present in the imipenem-cilastatin base combination — not a beta-lactamase inhibitor. Tazobactam is a classical beta-lactamase inhibitor paired with piperacillin. Vaborbactam is the cyclic boronate inhibitor paired with meropenem.

Correct Answer

C — Imipenem accumulates in renal impairment and at elevated concentrations acts as a gamma-aminobutyric acid receptor antagonist in the central nervous system

Rationale

Imipenem's seizure risk is concentration-dependent and is highest when the drug accumulates due to renal impairment, high doses, or pre-existing central nervous system pathology. At elevated concentrations, imipenem antagonizes gamma-aminobutyric acid-A receptors, reducing inhibitory neurotransmission and lowering the seizure threshold. This mechanism is shared with other beta-lactams at toxic concentrations, but imipenem has a structural feature that makes it the most potent gamma-aminobutyric acid-A antagonist among the carbapenems. Meropenem has substantially lower seizure liability at equivalent doses and is preferred for meningitis and in patients with seizure history. Cilastatin contributes no direct central nervous system toxicity.

Correct Answer

A — Meropenem achieves adequate cerebrospinal fluid concentrations with meningeal inflammation and carries substantially lower seizure risk than imipenem

Rationale

The two properties that make meropenem the carbapenem of choice for gram-negative meningitis are central nervous system penetration and seizure safety. With inflamed meninges, meropenem reaches bactericidal concentrations in the cerebrospinal fluid. Meropenem also has substantially lower seizure liability than imipenem — a key consideration when treating a central nervous system infection where drug accumulation and direct brain exposure could precipitate seizures. Imipenem is generally contraindicated for meningitis because its higher seizure potential makes it unsafe in this context. Cilastatin does not distribute into the cerebrospinal fluid and plays no role in central nervous system pharmacokinetics. Both carbapenems are predominantly renally eliminated.

Correct Answer

D — Ertapenem has the longest half-life of the carbapenems, enabling once-daily dosing, but lacks activity against Pseudomonas aeruginosa and Acinetobacter baumannii

Rationale

Ertapenem's distinguishing pharmacokinetic property is its long half-life of approximately 4 hours — the longest among the carbapenems — arising from extensive plasma protein binding. This enables once-daily intravenous or intramuscular dosing, making ertapenem the preferred carbapenem for outpatient parenteral antibiotic therapy of infections such as extended-spectrum beta-lactamase-producing Enterobacteriaceae that do not involve Pseudomonas aeruginosa or Acinetobacter baumannii. The absence of activity against these two gram-negative organisms is ertapenem's defining spectrum limitation, which simultaneously narrows its clinical niche and makes it a carbapenem-sparing agent for settings where broad antipseudomonal coverage is not needed. Ertapenem does not require cilastatin co-administration and has no activity against methicillin-resistant Staphylococcus aureus.

Correct Answer

B — Aztreonam binds penicillin-binding proteins of gram-negative bacteria with high selectivity and has negligible affinity for gram-positive or anaerobic penicillin-binding proteins

Rationale

Like all beta-lactams, aztreonam kills bacteria by inactivating penicillin-binding protein transpeptidases. Its gram-negative-only spectrum reflects the high structural selectivity of its penicillin-binding protein binding: aztreonam binds gram-negative penicillin-binding proteins with high affinity while having negligible affinity for the penicillin-binding proteins of gram-positive organisms or anaerobes. Without target binding, no antibacterial effect is possible regardless of penetration. This PBP selectivity is the primary pharmacological explanation — the structural features of the monocyclic aztreonam scaffold confer this specificity. The clinical implication is that aztreonam must always be combined with agents covering gram-positive organisms and anaerobes when polymicrobial coverage is required.

Correct Answer

A — New Delhi metallo-beta-lactamase cannot hydrolyze aztreonam because the enzyme requires a bicyclic beta-lactam scaffold for substrate binding, and aztreonam's monocyclic ring is not recognized

Rationale

Aztreonam's intrinsic stability to metallo-beta-lactamase hydrolysis is a structural property of its monocyclic (single-ring) scaffold. Class B metallo-beta-lactamases, including New Delhi metallo-beta-lactamase, have active sites configured for bicyclic beta-lactam substrates and do not efficiently recognize or hydrolyze the monocyclic aztreonam ring. This stability is the pharmacological basis for using aztreonam in combination regimens targeting New Delhi metallo-beta-lactamase producers. The challenge is that New Delhi metallo-beta-lactamase-producing organisms co-produce serine beta-lactamases (extended-spectrum beta-lactamases, AmpC) that do hydrolyze aztreonam — which is why avibactam must be co-administered to protect aztreonam from these co-produced serine enzymes.

Correct Answer

C — Cilastatin inhibits a renal tubular enzyme that would otherwise rapidly degrade imipenem before adequate systemic concentrations are reached

Rationale

Imipenem is a substrate for dehydropeptidase-I, an enzyme found on the brush border of renal tubular cells that hydrolyzes the beta-lactam ring of imipenem. Without inhibition, this renal tubular degradation would prevent imipenem from achieving systemic concentrations sufficient for antibacterial activity. Cilastatin is a specific inhibitor of dehydropeptidase-I that blocks this degradation, preserving imipenem for systemic distribution. Cilastatin has no antibacterial activity, does not inhibit bacterial beta-lactamases, and has no meaningful effect on seizure risk or central nervous system pharmacology. Meropenem, doripenem, and ertapenem are stable to dehydropeptidase-I hydrolysis and require no such protective co-agent.

Correct Answer

D — Carbapenems have no affinity for penicillin-binding protein 2a, the low-affinity transpeptidase encoded by mecA that sustains cell wall synthesis in methicillin-resistant Staphylococcus aureus

Rationale

Methicillin-resistant Staphylococcus aureus resistance to all beta-lactams, including carbapenems, is mediated by penicillin-binding protein 2a, the altered transpeptidase encoded by the mecA gene. Penicillin-binding protein 2a has an active site structure with extremely low affinity for all conventional beta-lactam antibiotics — carbapenems included. Because penicillin-binding protein 2a retains its transpeptidase function despite full drug exposure, the organism continues cell wall synthesis and survives. No carbapenemase is involved. Thick peptidoglycan does not prevent drug penetration in gram-positive organisms. Dehydropeptidase-I is a human renal enzyme, not a bacterial surface enzyme. The only beta-lactam with activity against methicillin-resistant Staphylococcus aureus is ceftaroline, which was engineered to bind penicillin-binding protein 2a despite its low-affinity active site.

Correct Answer

B — Aztreonam's monocyclic single-ring structure is not recognized as a substrate by New Delhi metallo-beta-lactamase, which requires a bicyclic beta-lactam scaffold for hydrolysis

Rationale

New Delhi metallo-beta-lactamase is a Class B metallo-beta-lactamase with an active site configured to hydrolyze bicyclic beta-lactam substrates — penicillins, cephalosporins, and carbapenems all share this bicyclic scaffold. Aztreonam is a monobactam with a single four-membered ring and no fused second ring. This monocyclic structure is structurally distinct from the bicyclic substrates the enzyme recognizes, so New Delhi metallo-beta-lactamase cannot efficiently hydrolyze it. This intrinsic stability is what makes aztreonam the antibacterial component of aztreonam-avibactam regimens against New Delhi metallo-beta-lactamase producers. Avibactam does not inhibit metallo-beta-lactamases and does not chelate zinc — it protects aztreonam from the serine beta-lactamases that these organisms co-produce.

Correct Answer

D — Imipenem's seizure risk is concentration-dependent and is substantially higher in patients with renal impairment or pre-existing central nervous system disease, making it unsafe in this patient

Rationale

Imipenem carries the highest seizure risk among the carbapenems. This risk is concentration-dependent: drug accumulation in renal impairment raises serum and central nervous system concentrations, increasing the likelihood of gamma-aminobutyric acid receptor antagonism and seizure provocation. The risk is further elevated in patients with pre-existing central nervous system disease, including epilepsy, where the seizure threshold is already lowered. In this patient — who has both chronic kidney disease and a seizure history — imipenem is the wrong choice. Meropenem is the preferred alternative: it retains broad carbapenem coverage, achieves adequate concentrations for gram-negative pneumonia, and has substantially lower seizure liability than imipenem at equivalent doses. Cilastatin has no pharmacokinetic interaction with antiepileptic drugs and does not affect dehydropeptidase-I activity in chronic kidney disease in a clinically relevant way.

Correct Answer

B — Aztreonam's monocyclic single-ring structure is structurally distinct from the bicyclic scaffolds of penicillins and cephalosporins and does not share cross-reactive antigenic determinants with them

Rationale

Penicillin allergy is mediated by hapten formation when the bicyclic penam scaffold's beta-lactam ring opens and binds covalently to proteins, generating antigenic determinants recognized by IgE antibodies in sensitized patients. Aztreonam's monocyclic structure generates different degradation products that do not share the cross-reactive antigenic determinants of penicillins or cephalosporins. For this reason, patients with documented penicillin allergy — including those with anaphylaxis — can generally receive aztreonam safely. The one established exception: aztreonam and ceftazidime share an identical side chain, so patients with documented ceftazidime hypersensitivity may cross-react with aztreonam and should avoid it. No modification of the beta-lactam ring or prodrug activation is involved in this safety profile.

Correct Answer

A — Ertapenem's long half-life enables once-daily outpatient dosing, and its lack of Pseudomonas aeruginosa coverage is not a limitation because that organism is not part of this infection

Rationale

Ertapenem has the longest half-life of the carbapenems, made possible by extensive plasma protein binding, which enables once-daily intravenous or intramuscular dosing. This pharmacokinetic property makes it the preferred carbapenem for outpatient parenteral antibiotic therapy. The absence of Pseudomonas aeruginosa and Acinetobacter baumannii coverage — ertapenem's defining spectrum limitation — is clinically acceptable here because neither organism is part of this patient's infection. Ertapenem does not require regulatory approval specifically for extended-spectrum beta-lactamase infections, it does not cover Pseudomonas aeruginosa at any dose, and it is renally rather than hepatically eliminated.

Correct Answer

C — Aztreonam is stable to New Delhi metallo-beta-lactamase hydrolysis because of its monocyclic structure; avibactam protects aztreonam from the serine beta-lactamases the organism co-produces

Rationale

The aztreonam-avibactam combination works through two complementary properties. Aztreonam's monocyclic beta-lactam ring is not recognized as a substrate by New Delhi metallo-beta-lactamase, giving it intrinsic stability to hydrolysis by this enzyme. However, organisms producing New Delhi metallo-beta-lactamase universally co-produce serine beta-lactamases that do hydrolyze aztreonam, which is why aztreonam cannot be used alone. Avibactam inhibits these co-produced serine enzymes, protecting aztreonam from destruction and allowing it to reach its penicillin-binding protein targets. Avibactam does not inhibit metallo-beta-lactamases and does not chelate zinc.